Название продукции:3,5-dichloro-4-[(6-chloropyridazin-3-yl)oxy]aniline

IUPAC Name:3,5-dichloro-4-[(6-chloropyridazin-3-yl)oxy]aniline

CAS:1581304-46-2
Молекулярная формула:C10H6Cl3N3O
Чистота:95%+
Номер в каталоге:CM1044504
Молекулярная масса:290.53

Упаковочная единица Доступно для заказа Цена ($) Количество

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:1581304-46-2
Молекулярная формула:C10H6Cl3N3O
Точка плавления:-
Smiles-код:NC1=CC(Cl)=C(OC2=CC=C(Cl)N=N2)C(Cl)=C1
Плотность:
Номер в каталоге:CM1044504
Молекулярная масса:290.53
Точка кипения:
Номер Mdl:
Хранение:

Category Infos

Pyridazines
Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

Column Infos

Resmetirom
Sept. 13, 2023, Madrigal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for resmetirom for the treatment of adult patients with NASH with liver fibrosis. 
Nonalcoholic steatohepatitis (NASH) is a more advanced form of nonalcoholic fatty liver disease (NAFLD). 
Resmetirom is designed to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell ballooning (hepatocyte cell death), and liver fibrosis that can lead to cirrhosis. Resmetirom is the only orally administered, small-molecule, liver-directed, truly β-selective THR agonist in Phase 3 development.